Effect of meditation on clinical symptoms and gray matter volume in chronic schizophrenia: a randomized controlled trial.

Eur Arch Psychiatry Clin NeurosciMay 19, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Mi Yang, Yuzheng Ma, Jialong Huang et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of meditation on clinical symptoms and gray matter volume in 58 male inpatients with chronic schizophrenia. Results showed that meditation significantly inhibited gray matter atrophy and correlated with reductions in PANSS scores, indicating its potential as a therapeutic intervention for alleviating symptoms in this population.

Key findings

  • Meditation significantly inhibited extensive regional atrophy of gray matter volume.
  • GMV change rate in the right thalamus correlated with reductions in PANSS positive, negative, and total scores.
  • The GMV change rate in the right insula was positively correlated with PANSS scores.
  • The right supplementary motor area GMV change rate correlated with negative PANSS scores.

Why it matters

Understanding the neurobiological effects of meditation on schizophrenia can enhance treatment options. This study suggests meditation may improve clinical symptoms and brain structure, offering a non-pharmacological approach to patient care.

Source

PubMed · PMID 42154270Free full text on PubMed Central

Published in Eur Arch Psychiatry Clin Neurosci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.